O-methylated rapamycin derivatives for alleviation and...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/44 (2006.01) A61K 31/445 (2006.01)

Patent

CA 2397354

The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal (see figure 8). Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.

L'invention concerne des méthodes permettant de soulager et d'inhiber un syndrome lymphoprolifératif chez un mammifère. Cette méthode consiste à administrer au mammifère un ou plusieurs dérivés de la rapamycine (y compris la rapamycine) (voir figure 8). L'invention concerne également une méthode permettant d'identifier des agents qui servent à soulager et à inhiber des syndromes lymphoprolifératifs, ainsi qu'une méthode permettant d'identifier des agents capables d'inhiber la métastase de tumeurs lymphatiques chez un mammifère.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

O-methylated rapamycin derivatives for alleviation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with O-methylated rapamycin derivatives for alleviation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and O-methylated rapamycin derivatives for alleviation and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1933427

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.